{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:12:32Z","timestamp":1793142752223,"version":"4.5.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,28]]},"DOI":"10.1182\/bloodadvances.2022007619","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T20:06:11Z","timestamp":1659729971000},"page":"525-528","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Ibrutinib in patients over 80 years old with CLL: a multicenter Italian cohort"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4687-7089","authenticated-orcid":false,"given":"Gianluigi","family":"Reda","sequence":"first","affiliation":[{"name":"1Hematology Unit, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Mattiello","sequence":"additional","affiliation":[{"name":"1Hematology Unit, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2587-7901","authenticated-orcid":false,"given":"Anna Maria","family":"Frustaci","sequence":"additional","affiliation":[{"name":"2Department of Haematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0271-7200","authenticated-orcid":false,"given":"Andrea","family":"Visentin","sequence":"additional","affiliation":[{"name":"3Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Romana","family":"Mauro","sequence":"additional","affiliation":[{"name":"4Hematology, Department of Translational and Precision Medicine, \u2018Sapienza\u2019 University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idanna","family":"Innocenti","sequence":"additional","affiliation":[{"name":"5Dipartimento Scienze Radiologiche ed Ematologiche, Divisione di Ematologia Fondazione Policlinico universitario A Gemelli, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[{"name":"6Azienda Ospedaliera of Cosenza, Cosenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Giannarelli","sequence":"additional","affiliation":[{"name":"7Biostatistic Unit, Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Noto","sequence":"additional","affiliation":[{"name":"1Hematology Unit, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Cassin","sequence":"additional","affiliation":[{"name":"1Hematology Unit, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Neri","sequence":"additional","affiliation":[{"name":"8Scientific Directorate Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8327-1396","authenticated-orcid":false,"given":"Luca","family":"Laurenti","sequence":"additional","affiliation":[{"name":"5Dipartimento Scienze Radiologiche ed Ematologiche, Divisione di Ematologia Fondazione Policlinico universitario A Gemelli, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tedeschi","sequence":"additional","affiliation":[{"name":"2Department of Haematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,2,16]]},"reference":[{"issue":"25","key":"2023081515544018400_bib1","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2023081515544018400_bib2","first-page":"2213","article-title":"Ibrutinib in CLL\/SLL: from bench to bedside (review)","volume":"42","author":"Zi","year":"2019","journal-title":"Oncol Rep"},{"issue":"12","key":"2023081515544018400_bib3","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"issue":"3","key":"2023081515544018400_bib4","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"2023081515544018400_bib5","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJMc2005943","article-title":"Ibrutinib for chronic lymphocytic leukemia with TP53 Alterations","volume":"383","author":"Ahn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023081515544018400_bib6","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/ejh.13499","article-title":"Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"105","author":"Aarup","year":"2020","journal-title":"Eur J Haematol"},{"issue":"12","key":"2023081515544018400_bib7","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1016\/j.clml.2021.07.022","article-title":"Real-world characteristics and outcome of patients treated with single-agent ibrutinib for chronic lymphocytic leukemia in Spain (IBRORS-LLC Study)","volume":"21","author":"Abrisqueta","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"2023081515544018400_bib8","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3324\/haematol.2016.147900","article-title":"Ibrutinib for relapsed\/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients","volume":"101","author":"UK CLL Forum","year":"2016","journal-title":"Haematologica"},{"issue":"10","key":"2023081515544018400_bib9","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1080\/10428194.2017.1292353","article-title":"Efficacy and toxicity of compassionate ibrutinib use in relapsed\/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG)","volume":"58","author":"Iskierka-Ja\u017cd\u017cewska","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2023081515544018400_bib10","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1002\/cam4.2998","article-title":"The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice","volume":"9","author":"Parikh","year":"2020","journal-title":"Cancer Med"},{"issue":"2","key":"2023081515544018400_bib11","doi-asserted-by":"crossref","first-page":"e0211228","DOI":"10.1371\/journal.pone.0211228","article-title":"Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis","volume":"14","author":"Caldeira","year":"2019","journal-title":"PLoS One"},{"issue":"11","key":"2023081515544018400_bib12","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.clml.2018.07.287","article-title":"Risk of major bleeding with ibrutinib","volume":"18","author":"Mock","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"2023081515544018400_bib13","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","article-title":"Ibrutinib-associated atrial fibrillation","volume":"4","author":"Ganatra","year":"2018","journal-title":"JACC Clin Electrophysiol"},{"issue":"1","key":"2023081515544018400_bib14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"22","key":"2023081515544018400_bib15","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"issue":"18","key":"2023081515544018400_bib16","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2023081515544018400_bib17","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/hon.2503","article-title":"Practical management of ibrutinib in the real life: focus on atrial fibrillation and bleeding","volume":"36","author":"Boriani","year":"2018","journal-title":"Hematol Oncol"},{"issue":"4","key":"2023081515544018400_bib18","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/hon.2655","article-title":"A\u00a0scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia","volume":"37","author":"Visentin","year":"2019","journal-title":"Hematol Oncol"},{"issue":"10","key":"2023081515544018400_bib19","doi-asserted-by":"crossref","first-page":"e657","DOI":"10.1503\/cmaj.091688","article-title":"Left atrial size and risk for all-cause mortality and ischemic stroke","volume":"183","author":"Bouzas-Mosquera","year":"2011","journal-title":"CMAJ"},{"issue":"1","key":"2023081515544018400_bib20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13045-018-0626-0","article-title":"Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study","volume":"11","author":"Reda","year":"2018","journal-title":"J\u00a0Hematol Oncol"},{"issue":"1","key":"2023081515544018400_bib21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00277-020-04094-3","article-title":"Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes","volume":"100","author":"Archibald","year":"2021","journal-title":"Ann Hematol"},{"issue":"6","key":"2023081515544018400_bib22","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41375-018-0344-1","article-title":"IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia","volume":"33","author":"Reda","year":"2019","journal-title":"Leukemia"},{"issue":"19","key":"2023081515544018400_bib23","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2015-04-639203","article-title":"Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2023081515544018400_bib24","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1038\/s41375-020-01030-2","article-title":"Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia","volume":"34","author":"Roeker","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"2023081515544018400_bib25","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood.2021012251","article-title":"COVID-19 in patients with hematologic malignancy","volume":"140","author":"Langerbeins","year":"2022","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/4\/525\/2071252\/blooda_adv-2022-007619-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/4\/525\/2071252\/blooda_adv-2022-007619-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:55:01Z","timestamp":1692114901000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/4\/525\/486122\/Ibrutinib-in-patients-over-80-years-old-with-CLL-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,2,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007619","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,16]]}}}